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White-matter injury is the most common cause of the adverse neurodevelopmental 
outcomes observed in preterm infants. Only few options exist to prevent perinatal brain 
injury associated to preterm delivery. 17-estradiol (E2) is the predominant estrogen in 
circulation and has been shown to be neuroprotective in vitro and in vivo. However, while E2 
has been found to modulate inflammation in adult models of brain damage, how estrogens 
influence glial cells response in the developing brain needs further investigations. Using a 
model of ibotenate-induced brain injury, we have refined the effects of E2 in the developing 
brain. E2 provides significant neuroprotection both in the cortical plate and the white matter 
in neonatal rats subjected to excitotoxic insult mimicking white matter and cortical damages 
frequently observed in very preterm infants. E2 promotes significant changes in microglial 
phenotypes balance in response to brain injury and the acceleration of oligodendrocyte 
maturation. Maturational effects of E2 on myelination process were observed both in vivo 
and in vitro. Altogether, these data demonstrate that response of glial cells to E2 could be 




Preterm birth is a common condition that affects roughly 1 in every 10 pregnancies, 
including in developed countries. In 2010, the Global Burden of Disease Study estimated that 
preterm birth was the most frequent cause of death and disability in children under the age 
of 5 years (Liu et al., 2012). Indeed, in addition to the immediate problem posed by the care 
of preterm infants and complications due to the immaturity of their organs, in 25-50% of 
them, prematurity is associated with long-term neurological disability, cerebral palsy, 
cognitive impairment and behavioral deficits, presenting enormous challenges to individuals, 
their families and society. This high rate of disability is partly a consequence of the improved 
survival of more and more immature infants, thanks to innovations in perinatal medicine 
over the past 30 years (Marlow et al., 2005). There are currently few treatment options to 
prevent brain injury associated to preterm delivery (Favrais et al., 2014). The need for novel 
strategies and care practices to curb the neurodevelopmental sequelae following premature 
birth is thus urgent. 
White-matter injury is the most common cause of the adverse neurodevelopmental 
outcomes observed in preterm infants (Back et al., 2014). In neonatal rodents, excitotoxic 
injury using glutamate agonists mimics some aspects of the diffuse white and grey matter 
abnormalities, collectively known as encephalopathy of prematurity, observed in the brain 
of human preterm neonates (Gressens et al., 1996; Volpe, 2009). Recent evidence suggests 
the existence of crosstalk between oligodendrocytes and their surroundings, including 
microglial cells and the hormonal environment. The injury-mediated activation of microglial 
cells plays a key role in disrupting the developmental maturation of the oligodendroglial 
lineage (Kaindl et al., 2009), and potentiates white matter injury and cognitive dysfunction 
into adulthood (Moretti et al., 2015).  
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Estrogens are lipophilic steroid hormones that can diffuse across the blood-brain barrier. 
However, the role of estrogens is not limited to the maintenance of female reproductive 
function and they have remarkable effects at various concentrations on several systems 
including the cardiovascular, immune, and nervous systems (Arevalo et al., 2015). 17-
estradiol (E2), an isomer of estradiol, is the predominant estrogen in circulation and has 
been shown to be neuroprotective in vitro and in vivo in various models of brain damage 
(Arevalo et al., 2010; Mc Carthy, 2008; Gerstner et al., 2007; Gerstner et al., 2009). E2 
directly promotes cell survival and synaptic plasticity, prevents axonal and dendritic pruning, 
and modulates levels of neurotransmitters and their receptors, leading to improved cell 
survival and neurite branching. However, while E2 has been found to modulate 
inflammation in adult models of brain damage, whether estrogens also influence the 
crosstalk between neural cells in the developing brain remains unclear. 
The aim of this study was therefore to explore whether E2 could protect the neonatal brain 
from excitotoxic brain injury through its effects on various glial cell types. To do this, we 
used both the model of ibotenate-induced brain injury mentioned above (Gressens et al., 
1996) and various primary cell cultures. 
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Materials and Methods 
All experiments were carried out in compliance with the ethical rules of the INSERM. The 
study and animal protocols were approved by the institutional review board (Bichat-Robert 
Debré ethics committee, Paris, France, approval number 2010-13/676-0010)  
 
Animals and model of excitotoxic brain lesions 
Rats (Sprague-Dawley, Janvier SAS, Le Genest-St-Isle, France) were housed in a temperature-
controlled room (19°C–23°C) with a 12 h/12 h light/dark cycle and with food and water ad 
libitum. Ten µg Ibotenate (Tocris, Bristol, UK) diluted in Phosphate Buffered Saline (PBS) was 
injected intracerebrally (i.c.) in postnatal day 5 (P5) rat pups as previously described (Pansiot 
et al., 2010). Ibotenate is a glutamate analogue that activates both N-methyl-D-aspartate 
(NMDA) and metabotropic receptors, but does not activate alpha-amino-3-hydroxy-5-
methyl-4-isoxazolepropionate (AMPA) or kainate receptors. Injections were performed using 
a 26-gauge needle and a 50 µl Hamilton syringe mounted on a calibrated microdispenser. 
The needle was placed in the frontoparietal area of the right hemisphere, 2.5 µm from the 
midline in the mediolateral plane, and 4 mm from the bregma in the rostrocaudal plane. 
Two 1 µl boluses of ibotenate were injected with an interval of 20 seconds between the two. 
The needle was left in place for an additional 20 seconds.  
 
-Estradiol injections 
The animals received a first injection of E2 12 hours before the ibotenate injection, and a 
second at the same time as ibotenate. Pre/per exposure injection regimen was chosen for 
covering the initial phase of brain injury process. Beta-Estradiol (E2) (Sigma, E8875) was first 
dissolved in DMSO and then diluted in PBS with a final concentration of 5% DMSO, and 
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injected intraperitoneally (i.p., 100µl each injection) at 4, 40 or 400µg/kg. Control animals 
received similar volumes of vehicle (PBS 5% DMSO). 
 
Dosage of estrogen 
Animals were anesthetized with isoflurane and blood collected by cardiac puncture at 3 time 
points: 3h after the first E2 injection (H3), 12h after the first injection (H12) and 3h after the 
second injection (H15). The clotted blood was centrifuged (7 min, 4000 rpm) and the serum 
pooled to obtain 200µl per time point (n = 4-5), frozen and stored at -80°C for hormonal 
measurements. E2 concentrations were measured using the Estradiol HS RIA kit 
(Immunodiagnostic systems, Paris, France, OD-67031). 
 
Determination of lesion size 
In each treatment group, 10–15 animals were sacrificed by decapitation 5 days after 
ibotenate injection (i.e. on P10). The brain was harvested, immediately fixed in 4% formalin 
and kept in this solution for 5 days before paraffin embedding. Coronal sections 16 µm thick 
were cut and every third section was mounted and stained with cresyl violet. The size of 
cortical and white matter lesions can be defined by their extent along 3 orthogonal axes: the 
mediolateral axis (in the coronal plane), the radial axis (also in the coronal plane, from the 
pial surface to the lateral ventricle), and the fronto-occipital axis (in the sagittal plane). In 
previous studies using this model (Husson et al., 2002), we observed an excellent correlation 
among measurements along the 3 axes. Based on these findings, we cut serial sections of 
the entire brain in the coronal plane for this study. This permitted the accurate and 
reproducible determination of the fronto-occipital extent of the lesion in the sagittal plane. 
We used this measurement as an index of lesion volume. All animals, and either males or 
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females injected with 400µg/kg were analyzed separately for lesion size determination. 
 
Immunohistochemistry 
In each experimental group, we studied 8 to 10 pups on postnatal days P6, P10 depending 
on experiments.  
Paraffin sections were immunolabeled with primary antibodies listed in Table 1 and labeling 
visualized using the streptavidin-biotin-peroxidase method and the chromogen 
diaminobenzidine, as previously described (Baud et al., 2003).  
 
RNA purification and real-time PCR 
Four hours after ibotenate injection, at least 8 animals per group (ibotenate +/- E2) were 
sacrificed by decapitation, the brains removed, a sample of the brain cortex and underlying 
white matter harvested at the i.c. injection site (ipsilateral) and at a similar location in the 
contralateral hemisphere, immediately snap-frozen in liquid nitrogen and stored at -80°C. 
Total RNA from the samples was extracted with the RNeasy mini kit according to the 
manufacturer’s instructions (Qiagen, Courtaboeuf, France). RNA quality and concentration 
were assessed by spectrophotometry using a NanoDropTM apparatus (Thermoscientifique, 
Wilmington, DE, USA). 1 µg of total RNA was subjected to reverse transcription using the 
IscriptTM cDNA synthesis kit (Bio-Rad, Marnes-la-Coquette, France). qRT-PCR was performed 
in duplicate for each sample on a CFX384 Real Time System (Bio-Rad), using SYBR Green 
Supermix (Bio-Rad) for 40 cycles. Amplification specificity was assessed by melting curve 
analysis. Primers were designed using Primer3 software and manufactured by Eurofins 
Genomics (Ebersberg, Germany). Primer sequences are summarized in Table 2. The 
expression of genes of interest was calculated relative to the expression of the reference 
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gene glyceraldehyde 3-phosphate dehydrogenase (GAPDH). Analyses were performed using 
Bio-Rad CFX Manager 3.0. 
Primary cell cultures 
Primary oligodendrocyte progenitor cell (OPC) cultures 
Mixed glial cells were isolated from the cortices of newborn (P0) Sprague–Dawley rat 
forebrains as previously described (Simonishvili et al, 2013). Briefly, tissues were 
enzymatically digested with trypsin and DNase I and then mechanically dissociated and 
plated in DMEM containing 10% FBS and 30% glucose with antibiotics. Mixed glial cells were 
grown in T75 flasks until they were confluent (10 days). Microglia were eliminated from the 
cultures by shaking the flasks on a rotary shaker for 1.5h at 260 rev./min and by using 
liposomal clodronate (Kumamaru et al., 2012). OPCs were isolated following an additional 
18h of shaking. The percentage of microglial cells contaminating OPCs culture is below 1%. 
OPCs were seeded onto poly-D-lysine-coated 8-well Ibidi µ-slides (Biovalley) at a density 105 
cells per well in a final volume of 250 µl/well. After 72h, OPC cultures were treated.  
Primary neuron cultures 
Cultured neurons were derived from the cerebral cortex of embryonic day (E) 17 rats. After 
dissection of the cortices and removal of the meninges, cortical cells were isolated as 
previously described (Baud et al., 2005). Cells were seeded either in 8-well Ibidi µ-slides 
(Biovalley) pre-coated with poly-L-lysine (Sigma) at 105 cells per well in a final volume of 250 
µl/well. Arabinocytidine hydrochloride (AraC, 5 µm, Sigma, C1768) was added on the 4th Day 
In Vitro (DIV) to stop astrocyte proliferation. Cultured neurons were exposed to treatments 
on DIV 10. 
Astrocyte/neuron co-cultures 
Astrocytes were derived from the cerebral cortex of postnatal day 1 (P1) rat pups as 
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previously described (Degos et al, 2013). Microglial cells were separated from primary mixed 
glia cultures at DIV 14 by shaking vigorously.  Neurons were prepared from the neocortex of 
E17 rat embryos as described above. One day before the plating of neurons, astrocytes were 
maintained in neuronal medium (DMEM) supplemented with Glutamax (Gibco, 35050-038), 
5% FBS, N-2 and B-27 (Gibco, respectively 15502-048 and 17504-044) and 0.01% penicillin-
streptomycin. Neurons were plated directly on the surface of confluent astrocytic 
monolayers at a density of 4.104 cells/cm2. Co-cultures were exposed to treatments on DIV 
10 for the neurons. 
 
Treatments and cell cultures assessment  
OPC cultures were treated with E2 (0.1µM) or vehicle, and then assessed after 24h exposure 
using immunocytochemistry. OPC cells were double-labeled using primary antibodies Olig2 
and MBP (Table 1) and secondary antibodies coupled to the green fluorescence marker 
Alexa488 (Lifetechnology) or the red fluorescent marker cyanine 3 (Jackson Immunoresearch 
Laboratories, USA). 
Neuronal cells cultures and astrocyte/neuron co-cultures were pre-treated by E2 (1-10µM or 
vehicle) 30 min before the excitotoxic insult. They were challenged during 5h using 300µM 
ibotenate and then assessed for cell death. To assess cell survival, we used Hoechst (Sigma, 
94403), staining all nuclei, and 7-Aminoactinomycin D (Life Technologies, A1310), staining 
only non-viable cells. 
 
Statistical analysis 
All data are reported as means +/- S.E.M. Statistical analysis of all data was performed using 
GraphPad PRISM version 5.0 (GraphPad Software, San Diego, CA). The normal distribution of 
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all results was assessed with the D’Agostino and Pearson omnibus normality test. To 
compare two groups with a normal distribution, a t-test was performed whereas in the 
absence of a normal distribution, a Mann–Whitney U test was used. For more than 2 groups, 




Effect of E2 on the size of excitotoxic lesions in the developing brain 
E2 was injected twice, 12h apart, in P4 rat pups according to the protocol described in the 
Method section. No difference in mortality rate or growth was detected between 
experimental groups. Table 3 shows serum concentrations of E2 in rat pups 3 and 12 hours 
(H3 and H12) after the first injection and 3 hours after the second injection (H15). Following 
the injection of 4, 40 and 400 µg/kg of E2, serum concentrations were found to be roughly 8-
, 50- and 280-fold higher respectively, compared to basal concentrations in P4 rat pups. At 
all E2 dosages, we observed a significant reduction in lesion size of the cortical plate on P10 
following i.c. ibotenate injection in P5 rat pups (Figure 1A-D). The two highest dosages (40 
and 400 µg/kg) were associated with a significant reduction in lesions size of the white 
matter (Figure 1A-D). The neuroprotective effect of 400 µg/kg E2 was found similar in males 
and females, in both cortex and white matter (Figure 1E, EF). Subsequent experiments were 
performed using 400 µg/kg of E2, because this dosage appeared to induce the maximal 
effect on brain damage and because it was in similar range than previously reported in the 
literature (Gerstner et al., 2007). 
 
Neuroprotective effect of E2 on the developing brain: impact of E2 on microglial phenotype 
and cytokine synthesis in vivo. 
Neuroprotection of the developing brain by E2 in our rat model has been next explored. 
Because neuro-inflammation is a phenomenon known to disrupt the maturation of the 
developing white matter and therefore myelination, E2 effect could thus be mediated by 
anti-inflammatory mechanisms.  
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The excitotoxic insult to the developing brain induced a dramatic and rapid (beginning 4h 
after i.c. injection) increase in the density of activated microglial cells (Husson et al., 2002). 
E2 was found to significantly reduce this microglial activation around the lesion site at P6 
(Figure 2A). At P10, excessive microglial activation was no longer observed in response to 
ibotenate challenge. Interestingly, E2 treatment was found associated with a significant 
decrease in the density of activated microglial cells in both hemispheres within the 
developing white matter (Figure 2B).  
To more precisely define the microglial activation, we next analyzed transcription levels for 
several markers of microglial phenotypes in response to ibotenate injection and E2 
treatment. The ibotenate insult was found to induce within 4h a significant increased 
synthesis of pro-inflammatory cytotoxic markers (Lgals3, CD86, Cox2, iNOS) and immuno-
modulatory markers (IL1rn, IL4ra), but reduced transcription of Arg1 and Mrc1, two 
repair/regeneration microglial markers (Figure 3). E2 treatment was found to reverse these 
changes for most of the markers and was therefore associated with modulation of the 
balance between microglial phenotypes. 
Figure 4 summarizes the effects of E2 on the transcription of genes encoding cytokines and 
other molecules involved in inflammation and immune function in contralateral hemisphere 
to the excitotoxic insult (Veh and E2 groups) and in ipsilateral hemisphere to the ibotenate 
injection  (Ibo+Veh and Ibo+E2 groups). E2 did not induce any significant changes in cytokine 
synthesis in the hemisphere contralateral to the ibotenate insult. In contrast, 4 hours after 
ibotenate injection, gene expression levels of various cytokines were found to be modified in 
brain samples harvested around the ipsilateral white matter and cortical lesion. E2 
treatment was associated with a rapid (within 4h) and significant reversal of the ibotenate-
induced change in the expression of genes encoding interleukin (IL) 6, IL1-beta and 
 13 
prostaglandin D2 synthase (PTGDS) (Figure 4).  
Altogether, these data strongly suggest that E2 is capable of reversing the inflammation 
associated with white matter and cortical lesions induced in the developing brain by 
excitotoxicity due to ibotenate, a glutamate agonist. 
 
Neuroprotective effect of E2 on the developing white matter: impact of E2 on myelination 
and oligodendroglial maturation in vivo and in vitro 
Besides its effect on neuroinflammation, we asked the question whether E2 could improve 
myelination and promote the oligodendroglial maturation.  
After ibotenate challenge in vivo, E2 was found to be associated with a significant increase in 
the density of APC-positive mature oligodendrocytes both within the white matter adjacent 
to the injury site and in the ipsilateral cingulate white matter, compared to vehicle 
treatment (Figure 5A, 5C). In contrast, no detectable effect was observed regarding the 
density of all Olig2-positive oligodendrocytes in the same regions of interest (Figure 5B). In 
addition, myelin fiber density, as measured by labeling for MBP, was also found to be 
significantly increased following E2 treatment in two separate uninjured white matter areas 
(cingulum and lateral corpus callosum) (Figure 5D, 5E). This is in accordance with the 
downregulation of PDGRgene transcription induced by E2, without significant changes in 
the expression of Sox10, Nkx2.2 or p27kip1 (Figure 5F).  
In primary OPC cultures, 24h of exposure to E2 at very low concentration (0.1 µM) as 
compared to vehicle was associated with increased density of MBP-positive sheets without 
changing the density of Olig2-positive cells (Figure 5G-I). These data are consistent with 




Role of astroglial cells in E2 neuroprotection in cerebral cortex and neurons 
To better delineate the potential role of glial cells in E2-induced neuroprotection observed in 
vivo, we next investigated the effect of this hormone on astrocytes both in vivo and in vitro. 
We first hypothesized that the in vivo beneficial effect of E2 on the cortical plate could be 
mediated through astroglial cells. We observed that E2 cortical neuroprotection was not 
associated with reduced astroglial activation in response to cortical injury induced by 
ibotenate injection (Figure 6A). In addition, we found that E2 promoted upregulation of 
TGF1 and GDNF gene expression when cortex was subjected to excitotoxic challenge 
(Figure 6B). These growth factors were known to play a role in astrocytes-induced survival of 
neurons (Platania et al., 2005; Dhandapani et al., 2005).  We next replicated in vitro our in 
vivo model of excitotoxic injury by subjecting during 5h neuronal cells alone to 300 µM of 
ibotenate, a concentration known to induce significant reduction in neuronal survival (Degos 
et al., 2013). E2, at any concentrations used (1, 10 µM) after 30 min pretreatment duration 
was not capable of significantly reducing ibotenate-induced neuronal death in culture 
(Figure 6C). We therefore asked whether the cortical neuroprotection observed in vivo was 
indeed related mediated by astrocytes in response to ibotenate. We used co-cultures in 
which neurons were in contact with a confluent astrocytic monolayer. Under these 
experimental conditions, significant neuroprotection has been already observed without E2 
(Figure 6C). The addition of E2 (1-10 µM) to the co-cultures 30 min before excitotoxic 
challenge was associated with full and much more pronounced protection against neuronal 





In this study, we demonstrate that E2 exposure significantly reduces lesion size in both the 
cortical plate and white matter in rat pups subjected to excitotoxic brain injury. While some 
reports have already shown that estradiol is partially protective in a neonatal model of brain 
damage induced by kainic acid (Mc Carthy, 2008; Hilton et al., 2004), the precise 
mechanisms have remained unclear. Here, we have better defined the main effects of E2 in 
the developing brain, in vivo and in vitro, and provide new insight into the cellular crosstalk 
that mediates the response to E2 treatment:  
- first, E2 has significant effect on the acceleration of oligodendrocyte maturation in 
the developing brain, 
- second, the E2-mediated neuroprotection observed in rat pups was associated with 
significant changes in microglial phenotype in response to brain injury.  
- third, astrocytes appear to play a key role in mediating E2 neuronal effect.  
The developing brain expresses high levels of receptors for estrogens derived from the 
maternal circulation, fetal gonads, and local synthesis in the brain. Several animal studies 
have demonstrated that estradiol of both gonadal and brain origin is neuroprotective in 
adults (Arevalo et al., 2015). In particular, studies in female rodents have shown that 
decreasing plasma estradiol concentrations by ovariectomy exacerbates brain damage under 
neurodegenerative conditions (Azcoitia et al., 1999; Azcoitia et al., 2011; Yue et al., 2005; 
Ding et al., 2013; Overk et al., 2012). Estradiol could be also neuroprotective in humans, as 
aging and menopause are thought to potentiate age-related cognitive impairment and 
Alzheimer’s disease (Scott et al., 2012).  
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In vitro studies investigating the mechanism of action of estradiol have shown that it 
promotes the survival of mature neurons even in the absence of glial cells (Chowen et al., 
1992; Valles et al., 2008). In our study, however, no concentration of E2 tested had any 
effect on primary neuronal cultures subjected to ibotenate injury but neuroprotective 
effects on neurons were observed when astrocytes and neurons were co-cultured. These 
findings were in accordance with other reports (Dhandapani and Brann, 2003, 2007). 
Furthermore, TGF1 and GDNF gene expression was found to be upregulated by E2, 
consistently with the central role of astrocytes in E2-mediated neuronal protection against 
excitotoxic insult as previously shown (Platania et al., 2005; Dhandapani et al., 2003, 2005). 
Astrocytic glial cells derived from rat neonatal cortex have been shown to express both 
estrogen receptors (ER)  and  proteins in both the nuclear fractions and plasma-
membrane fractions (Chaban et al., 2004). ERs are also expressed in the oligodendroglial 
plasma membrane and decrease with maturation (Arvanitis et al., 2004; Gerstner et al., 
2009). Because brain injury induces the synthesis of estradiol in these cells, ERs likely play a 
key role in this estradiol-mediated neuroprotection. Further studies are ongoing to explore 
endogenous steroidogenesis and the pattern of expression of aromatase, the enzyme 
responsible for the conversion of testosterone into estrogens, in dividing neural precursors 
harvested from the developing rat brain. Indeed, increased aromatase activity in astrocytes, 
which do not express this enzyme under basal conditions in adult rodents, appears to play a 
key role in the neuroprotective effects of estradiol both in animals and humans (Garcia-
Segura et al., 1999; Azcoitia et al., 2001). This mechanism needs to be further explored in the 
developing brain, in order to understand the crucial involvement of astrocytes in 
neuroprotection in vitro in our study.  
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The role of glial cells in the neuroprotective properties of estradiol has been mainly 
described in in vitro systems, in which estradiol appears to act on glial and endothelial cells 
to maintain the function of the neurovascular unit in vivo, to control neuroinflammation and 
to maintain the function of neuronal circuits (Arevalo et al., 2010; Spence et al., 2013; 
Dhandapari and Brann, 2007). Here we demonstrate that estradiol is also able to enhance 
oligodendrocyte maturation and myelination in the developing brain, a key phenomenon 
associated with reduced brain damage as previously reported in several models of neonatal 
brain injury (Van Steenwinckel et al., 2014). The protective effect of E2 against hypoxic-
ischemic injury to developing oligodendrocytes and white matter has been already reported 
(Gerstner et al., 2009), but not following excitotoxic injury in the immature brain. 
Not surprisingly, E2 also demonstrated anti-inflammatory properties in the present study in 
a context of excitotoxic insult. Indeed, several reports have shown that both 17β-E2 and 
selective estrogen receptor modulators could mediate anti-inflammatory pathways in 
microglial cells in other models (Tapia-Gonzalez et al., 2008; Bruce-Keller et al., 2000). 17β-
E2 has previously been shown to prevent the production and secretion of pro-inflammatory 
cytokines such IL-1β, IL-6, and TNFα, through the inhibition of NFκB signaling and the 
transcription of pro-inflammatory genes (Nadkarni and McArthur, 2013). Here, we found 
that neuroinflammation induced by the excitotoxic insult was one of the main targets of E2 
treatment, leading to both a downregulation of genes encoding pro-inflammatory molecules 
and a reduction in the density of activated microglia. A recent study has reported that sex 
steroids could regulate hypoxia-induced inflammatory responses and the microglial 
phenotype switch in rat primary microglia in vitro (Habib et al., 2014). Our study refines the 
microglial phenotype in response to E2 treatment in vivo, and reveals that E2 tilts the 
balance in favor of repair and immunomodulatory factors. In addition, Favrais et al. have 
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demonstrated that neuroinflammation induces a blockade in the maturation of the 
oligodendroglial lineage (Favrais et al., 2011). The attenuation of neuroinflammation could 
therefore promote oligodendrocyte maturation in treated rat pups.   
In addition to the effect of E2 on brain lesion size, neuroinflammation and cell lineages, long-
term behavioral studies are also needed to confirm functional benefit of this 
neuroprotective strategy. A recent study demonstrated that estradiol improves functional 
outcome following spinal cord injury in rat (Mosquera et al., 2014). In stroke, E2 induces 
increases in neurogenesis and contributes to functional recovery (Li et al., 2011). 
 
Although epidemiological and animal studies point to estrogen as an important factor in 
neuroprotection, future clinical translation might be not simple for several important 
reasons. First, supra-physiological levels used here and elsewhere for inducing 
neuroprotective effect in rodents were not compatible with clinical translation. Second, the 
functions of estrogens are intimately associated with those of progesterone and androgens 
(Chowen et al., 2000), making it difficult to consider each independently with respect to 
neuroprotection. Finally, because the role of estrogens in neuroprotection may be indirect, 
through actions on other organs which then impinge upon the health of the brain. The 
therapeutic role of estrogens in neuroprotection could benefit from the development of 
selective estrogen receptor modulators (SERMs) that preferentially target one estrogen-
sensitive tissue over others (Merchenthaler et al., 2003; Azcoitia et al., 2011; Arevalo et al., 
2012). While the specific actions of SERMs in the CNS need to be evaluated, they may 
ultimately prove useful in targeting the neuroprotective effects of estrogen analogs without 
activating neuroendocrine functions. 
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In conclusion, E2 provides significant neuroprotection both in the cortical plate and the 
white matter in neonatal rats subjected to excitotoxic brain injury. This effect is 
implemented through the interactions of multiple glial cell types in the injured brain (Johann 
and Beyer, 2013). Further in vivo studies are needed to better understand the signaling 
pathways involved in the response of glial cells to estrogenic compounds and to assess their 
long-term behavioral effect before their translation to the clinical setting. In this respect, 
SERMs could constitute an interesting and novel approach to modulate microglial activation 
and CNS inflammation in neonates at risk of brain damage. 
 20 
Tables and Figure legends 
 
Table 1: Antibodies and markers used in the experiments. 
Table 2: Primer sequences used in the experiments. 
Table 3: Serum E2 concentrations 3, 12 and 15h after the onset of the treatment (two 
injections were carried out, at H0 and H12) (values are expressed in pg/mL). 
 
Figure 1: E2 confers neuroprotection against excitotoxic brain lesions in neonatal rats.  
A, B. Quantitative analysis of lesion size (fronto-occipital extent) in the cortical plate (A) and 
white matter (B) following the i.c. injection of ibotenate (ibo) in P5 rat pups (n=10-15) with 
and without E2 pre-exposure (2 doses of 4, 40 or 400 µg/kg were injected 12h and at the 
time of ibotenate challenge). 
*: p<0.05 and ***: p<0.001 for comparisons between the treated groups and Veh group 
using one-way ANOVA with Dunnett’s correction. 
C, D. Cresyl-violet–stained sections showing brain lesions induced by ibotenate intra-
cerebrally injected on P5 and observed on P10. E2 reduced the size of the ibotenate-induced 
cortical lesion (red arrow) and white matter cyst (blue arrow). Bar = 50 µm; LV: lateral 
ventricle.  
E, F. Quantitative analysis of cortical (E) and white matter (F) lesion size following the i.c. 
injection of ibotenate  in P5 females and males (n=9 in each group) with and without E2 pre-
exposure (2 doses of 400 µg/kg). *: p<0.05, **: p<0.01 and ***: p<0.001 for comparisons 




Figure 2: Impact of E2 treatment on excitotoxic white matter injury in rat pups. 
Quantitative analysis of the density of activated microglia in the white matter surrounding 
the cystic excitotoxic lesion (ipsilateral to ibotenate injection) and in the contralateral white 
matter. Cell densities were evaluated by tomato lectin labeling at 24h (A) and ED1 
immunoreactivity at 5 days (B) in animals treated either by 400 µg/kg E2 or vehicle; n=8-10 
in each group.  
*: p<0.05, **: p<0.01 and ***: p<0.001 for comparisons between contralateral hemisphere 
in vehicle-treated animals and the other experimental groups using one-way ANOVA with 
Dunnett’s correction. ##: p<0.01 and ###: p<0.001 for comparisons between the two groups 
indicated, using a one-tailed t-test. 
 
Figure 3: Early impact of E2 on gene expression levels of various microglial phenotypic 
markers in P5 rat pups 4h after ibotenate insult. Veh: contralateral hemisphere in vehicle-
treated animals; E2: contralateral hemisphere in animals treated by 400 µg/kg E2; ibo+Veh:  
ipsilateral hemisphere in vehicle-treated animals; Ibo+E2: ipsilateral hemisphere in animals 
treated by 400 µg/kg E2. Lgals3, CD86, Cox2 and iNOS are pro-inflammatory cytotoxic 
markers, Mrc1 and Arg1 are repair/regeneration markers, IL1rn and IL4ra are 
immunomodulatory markers; n=8 in each group. 
*: p<0.05, **: p<0.01 and ***: p<0.001 for comparisons between contralateral hemisphere 
in vehicle-treated animals and the other experimental groups using one-way ANOVA with 
Dunnett’s correction. #: p<0.05, ##: p<0.01 and ###: p<0.001 for comparisons between the 
two groups indicated, using a one-tailed t-test. 
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Figure 4: Early impact of E2 on gene expression levels of various cytokines and 
prostaglandins-related proteins. 
Quantitative PCR were performed in P5 rat pups 4h after ibotenate insult. Veh: contralateral 
hemisphere in vehicle-treated animals; E2: contralateral hemisphere in animals treated by 
400 µg/kg E2; ibo+Veh:  ipsilateral hemisphere in vehicle-treated animals; Ibo+E2: ipsilateral 
hemisphere in animals treated by 400 µg/kg E2; n=8 in each group. 
*: p<0.05, **: p<0.01 and ***: p<0.001 for comparisons between contralateral hemisphere 
in vehicle-treated animals and the other experimental groups using one-way ANOVA with 
Dunnett’s correction. #: p<0.05 and ##: p<0.01 for comparisons between the two groups 
indicated, using a one-tailed t-test. 
 
Figure 5: Effect of E2 on oligodendrocyte maturation with or without an excitotoxic 
challenge.  
A-C: Quantitative analysis of the density of APC-positive (A) and Olig2-positive (B) cells in 
two regions ipsilateral to the ibotenate injection: close to the white matter damage (WMD) 
and within the cingulate white matter (CWM). Regions analyzed are indicated by boxes 
superposed on cresyl-violet–stained sections showing brain lesions induced by i.c. ibotenate 
injected on P5 and observed on P10 (C). Bar = 50 µm; LV: lateral ventricle; n=8-10 in each 
group. *: p<0.05, **: p<0.01, for comparisons between Veh and E2 groups, using a one-
tailed t-test. 
D: Quantitative analysis of the optical density of myelinated fibers in the cingulate white 
matter and lateral corpus callosum in P10 rat pups without excitotoxic challenge; n=8-10 in 
each group. *: p<0.05 for comparisons between Veh and E2 groups, using a one-tailed t-test. 
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E: Representative photomicrographs of MBP-positive fibers in the cingulate white matter on 
P10 in rat pups treated with 400 µg/kg of E2 on P5 (+E2) compared to rat pups injected with 
Vehicle (+Veh), without ibotenate challenge. Bar = 50 µm. 
F: Quantitative analysis of gene expression levels of PDGFR, Sox10, Nkx2.2 and p27kip1 in 
P5 rat pups 4h after treatment with 400 µg/kg E2 (black bars) compared to untreated 
controls (Veh, white bar); n=8 in each group. 
**: p<0.01 for comparisons between the treated groups and Veh, using one-way ANOVA 
with Dunnett’s correction.  
G-I: The density of Olig2-positive cells and ratio of the optical density (OD) of myelin basic 
protein (MBP) to the density of Olig2-positive cells after 24h of exposure to either vehicle or 
0.1 µM E2 in oligodendroglial precursor cells in vitro.  
**: p<0.01 for comparisons between the two groups indicated, using a one-tailed t-test. 
 
Figure 6: Role of astrocytes in the beneficial effects of E2 on neuronal cells subjected to an 
excitotoxic insult in vivo and in vitro. 
A. Quantitative analysis of the density of GFAP-positive cells in the somato-sensory cortex in 
ipsilateral (ibotenate injured) and contralateral (no injury) hemispheres. No difference was 
observed between Veh and E2 groups in each hemisphere, using a one-tailed t-test; n=8-10 
in each group. 
B. Quantitative analysis of the transcription of genes involved in astrocytic-induced 
neuroprotection in cortical samples from P10 rat pups after ibotenate insult. Veh: 
contralateral hemisphere in vehicle-treated animals; E2: contralateral hemisphere in animals 
treated by 400 µg/kg E2; ibo+Veh:  ipsilateral hemisphere in vehicle-treated animals; Ibo+E2: 
ipsilateral hemisphere in animals treated by 400 µg/kg E2; n=8 in each group. 
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*: p<0.05, **: p<0.01 and ***: p<0.001 for comparisons between the two groups indicated, 
using one-way ANOVA with Dunnett’s correction.  
C. Three hundred µM ibotenate exposure during 5h was found to induce significant neuronal 
cell death. E2 has no effect on ibotenate-induced cell death in neurons only (***: p<0.001, 
using one-way ANOVA with Bonferroni correction) significant neuroprotection has been 
observed when using a two-layer co-culture system in which neurons were in contact with 
astroglial cells (##: p<0.01, comparison between neurons only and co-cultures subjected to 
300 µM ibotenate, without E2). This neuroprotection was found significantly more 
pronounced when the system was exposed to E2 (1 and 10 µM). §§§: p<0.001 for 
comparisons between groups exposed to E2 and without E2 using one-way ANOVA with 
Dunnett’s correction.  
D. Necrotic cell death in the neuronal layer of the co-culture system as seen using 7-
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